← GLP-1 receptor agonists × blood pressure

SynthesisDiabetes research and clinical practice2015

Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.

Feng Sun et al.PubMed ↗Publisher ↗

  • GLP-1RAslooks good hereLower systolic blood pressure.Randomised, small.
  • Exenatide-10 μg-twice-dailylooks good hereLower diastolic blood pressure, lower incident hypertension.Randomised, small.
  • Exenatide (2 mg once weekly)no clear effectHigher heart rate.Nothing cleared the noise.
  • Liraglutide 1.2 mg once dailyno clear effectHigher heart rate.Nothing cleared the noise.

What the trial testedrandomised · 2015

Randomised vs placebo, insulin, and sulfonylureas

Probably lowered systolic blood pressure

−1.84mmHg−3.48 to −0.20

GLP-1RAs vs placebo, insulin, and sulfonylureas

As reported

difference −1.84 mmHg, 95% CI −3.48 to −0.20

Randomised vs placebo, insulin, and sulfonylureas

Probably lowered systolic blood pressure

−4.60mmHg−7.18 to −2.03

GLP-1RAs vs placebo, insulin, and sulfonylureas

As reported

difference −4.60 mmHg, 95% CI −7.18 to −2.03

Randomised vs placebo

Probably lowered diastolic blood pressure

−1.08mmHg−1.78 to −0.33

exenatide-10 μg-twice-daily vs placebo

As reported

difference −1.08 mmHg, 95% CI −1.78 to −0.33

Randomised vs sulfonylureas

Probably lowered incident hypertension

−60%−84% to −18%

exenatide-10 μg-twice-daily vs sulfonylureas

Bigger than 9 in 10 on the map

As reported

OR 0.40, 95% CI 0.16–0.82

+3 more in the walkthrough ↓

Who was studied, and how

people with hypertension, in this paper

The trial randomly assignedassigned by chance

GLP-1RAs
placebo, insulin, and sulfonylureas

Probably lowered systolic blood pressure−1.84

randomised

The trial randomly assignedassigned by chance

exenatide-10 μg-twice-daily
placebo

Probably lowered diastolic blood pressure−1.08

randomised

the abstract, start to end

… systolic blood pressure with range from -1.84 mmHg (95% CI: -3.48 to -0.20) to -4.60 mmHg (95% CI: -7.18 to -2.03).

… only for exenatide-10 μg-twice-daily (-1.08 mmHg, 95% CI: -1.78 to -0.33).

… mg once daily) increased heart rate by 3.35 (95% CI: 1.23-5.50), 2.06 (95% CI: 0.43, 3.74), and 2.35 (95% CI: 0.94-3.76) beats/min …

… μg-twice-daily and sulfonylureas (OR, 0.40, 95% CI: 0.16, 0.82).

← favours treatmentfavours comparator →
could be chance
Systolic blood pressureGLP-1RAs vs placebo, insulin, and sulfonylureas
−1.84−3.48 to −0.20
Systolic blood pressureGLP-1RAs vs placebo, insulin, and sulfonylureas
−4.60−7.18 to −2.03
Diastolic blood pressureexenatide-10 μg-twice-daily vs placebo
−1.08−1.78 to −0.33
Heart rateExenatide (2 mg once weekly) vs placebo
3.351.23–5.50
Heart rateliraglutide 1.2 mg once daily vs placebo
2.060.43–3.74
Heart rateliraglutide (1.8 mg once daily) vs placebo
2.350.94–3.76
Incident hypertensionexenatide-10 μg-twice-daily vs sulfonylureas
OR 0.400.16–0.82
GLP-1 receptor agonistsBlood pressureAdverse events & safety

GLP-1 receptor agonists × blood pressurehelps?mixed

unlikelylikely
0.50not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 7

141 papers cite itlatest 60 shown

2015
…
2016
2017
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 26358202